Filing Flows › Corcept Therapeutics (CORT) › Operating margin
Corcept Therapeutics (CORT) operating margin by quarter
Corcept Therapeutics' operating margin was 33.7% in Q3 2026 (third quarter 2026), +17.6 pts from Q2 2026. Over the last 6 quarters it ranged from 2.2% (Q1 2025) to 33.7% (Q3 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 33.7% | +17.6 pts | +28.8 pts |
| Q2 2026 | 16.1% | +13.9 pts | +2.4 pts |
| Q4 2025 | 2.2% | -2.7 pts | — |
| Q3 2025 | 4.9% | -8.8 pts | — |
| Q2 2025 | 13.7% | +11.5 pts | — |
| Q1 2025 | 2.2% | — | — |
Q3 2026 at a glance
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Questions
What is Corcept Therapeutics' operating margin?
Corcept Therapeutics' operating margin was 33.7% in Q3 2026 (third quarter 2026), +17.6 pts from Q2 2026.
How has Corcept Therapeutics' operating margin changed?
Over the last 6 quarters it ranged from 2.2% (Q1 2025) to 33.7% (Q3 2026).